SCHEMBL7183569

SCHEMBL7183569

CCCCOc1cc(OCCCC)c(PC(=O)c2c(Cl)cccc2OC)c(OCCCC)c1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
DPP4 P27487 1/20 0.40
PPARA Q07869 3/20 0.40
PPARG P37231 2/20 0.40
PPARD Q03181 1/20 0.40
ELANE P08246 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
FAAH O00519 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177969 0.97 MAPT (0.41) MAPTTDP1L3MBTL1PPARAELANE
SCHEMBL7190076 0.96 PPARA (0.42) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL7186427 0.94 ELANE (0.43) MAPTTDP1L3MBTL1KMT2ADPP4
SCHEMBL7187854 0.94 FAAH (0.41) MAPTTDP1L3MBTL1PPARAPPARG
SCHEMBL7181299 0.93 PPARA (0.41) MAPTL3MBTL1PPARAPPARGTHRA
SCHEMBL7182812 0.91 THRB (0.44) THRATHRB
SCHEMBL7180843 0.90 L3MBTL1 (0.42) MAPTTDP1L3MBTL1MEN1KMT2A
SCHEMBL7177416 0.90 PPARA (0.43) MAPTMEN1KMT2APPARATHRA
SCHEMBL7182256 0.90 THRB (0.46) MAPTMEN1KMT2ATHRATHRB
SCHEMBL7175442 0.89 L3MBTL1 (0.42) MAPTTDP1L3MBTL1ELANESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885TDP1 4234/4885L3MBTL1 302/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885TDP1 4275/4885L3MBTL1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.